BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hardy J, Bélisle S, Van der Linden P. Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials. The Annals of Thoracic Surgery 2008;86:1038-48. [DOI: 10.1016/j.athoracsur.2008.05.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hardy J, Van der Linden P, Fergusson D. If we have bandwagons, magic bullets, and theoretical constructs, why do we need randomized clinical trials in transfusion medicine and perioperative hemostasis? Can J Anesth/J Can Anesth 2011;58:240-5. [DOI: 10.1007/s12630-010-9444-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Esper RC, Estrada IE, de la Torre León T, Gutiérrez AO, López JA. Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer. J Intensive Care 2014;2:47. [PMID: 25705408 DOI: 10.1186/s40560-014-0047-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
3 Daban J, de Saint Maurice G, Blot R, Ausset S. Hemostatic Agents: Which Is Better? Journal of Trauma: Injury, Infection & Critical Care 2010;69:1636. [DOI: 10.1097/ta.0b013e3181feba0b] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Curry N, Stanworth S, Hopewell S, Dorée C, Brohi K, Hyde C. Trauma-induced coagulopathy--a review of the systematic reviews: is there sufficient evidence to guide clinical transfusion practice? Transfus Med Rev. 2011;25:217-231.e2. [PMID: 21377318 DOI: 10.1016/j.tmrv.2011.01.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
5 Habib AM, Mousa AY, Al-Halees Z. Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery. J Saudi Heart Assoc 2016;28:222-31. [PMID: 27688669 DOI: 10.1016/j.jsha.2016.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Dries DJ. The contemporary role of blood products and components used in trauma resuscitation. Scand J Trauma Resusc Emerg Med 2010;18:63. [PMID: 21106098 DOI: 10.1186/1757-7241-18-63] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
7 Edmunds LH Jr. Managing fibrinolysis without aprotinin. Ann Thorac Surg 2010;89:324-31. [PMID: 20103278 DOI: 10.1016/j.athoracsur.2009.10.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944-982. [PMID: 21353044 DOI: 10.1016/j.athoracsur.2010.11.078] [Cited by in Crossref: 812] [Cited by in F6Publishing: 671] [Article Influence: 73.8] [Reference Citation Analysis]
9 Rajpurkar M, Croteau SE, Boggio L, Cooper DL. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med 2019;10:335-40. [PMID: 31572039 DOI: 10.2147/JBM.S219573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010;41:48-53. [PMID: 19959538 DOI: 10.1161/STROKEAHA.109.561712] [Cited by in Crossref: 84] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
11 Jackson LR, Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 2014;37:380-91. [DOI: 10.1007/s11239-013-0958-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
12 Schols SE, Heemskerk JW, van Pampus EC. Correction of coagulation in dilutional coagulopathy: use of kinetic and capacitive coagulation assays to improve hemostasis. Transfus Med Rev 2010;24:44-52. [PMID: 19962574 DOI: 10.1016/j.tmrv.2009.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
13 Godier A, Ozier Y, Susen S. Le ratio transfusionnel PFC/CGR 1/1 : un phénomène de mode basé sur des preuves ? Annales Françaises d'Anesthésie et de Réanimation 2011;30:421-8. [DOI: 10.1016/j.annfar.2011.02.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Phillips LE, Mclintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA. Recombinant Activated Factor VII in Obstetric Hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry. Anesthesia & Analgesia 2009;109:1908-15. [DOI: 10.1213/ane.0b013e3181c039e6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
15 Godier A, Samama C, Susen S. Prise en charge en 2013 de l’hémorragie aiguë massive : réponses à sept questions. Transfusion Clinique et Biologique 2013;20:55-8. [DOI: 10.1016/j.tracli.2013.02.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Wade CE, Eastridge BJ, Jones JA, West SA, Spinella PC, Perkins JG, Dubick MA, Blackbourne LH, Holcomb JB. Use of recombinant factor VIIa in US military casualties for a five-year period. J Trauma 2010;69:353-9. [PMID: 20699744 DOI: 10.1097/TA.0b013e3181e49059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
17 Zhou JJ, Hemphill C, Walker CT, Farber SH, Uribe JS. Adverse Effects of Perioperative Blood Transfusion in Spine Surgery. World Neurosurg 2021;149:73-9. [PMID: 33540100 DOI: 10.1016/j.wneu.2021.01.093] [Reference Citation Analysis]
18 Lin Y, Stanworth S, Birchall J, Doree C, Hyde C, Stanworth S. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005011.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
19 Hardy J, Bélisle S, Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Current Opinion in Anaesthesiology 2009;22:95-9. [DOI: 10.1097/aco.0b013e32831a40a3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
20 Durand M, Godier A, Notet V, Hacquard M, Collignon O, Corbonnois G, Plénat F, Carteaux JP, Lecompte T. Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits. Eur J Anaesthesiol 2011;28:51-6. [PMID: 20625303 DOI: 10.1097/EJA.0b013e32833cf067] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Nalla BP, Freedman J, Hare GM, Mazer CD. Update on blood conservation for cardiac surgery. J Cardiothorac Vasc Anesth 2012;26:117-33. [PMID: 22000983 DOI: 10.1053/j.jvca.2011.07.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mercier FJ, Bonnet MP. Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage. Curr Opin Anaesthesiol 2010;23:310-6. [PMID: 20216063 DOI: 10.1097/ACO.0b013e32833835a2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
23 Chang Z, Chu X, Liu Y, Liu D, Feng Z. Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials. J Crit Care 2021;62:164-71. [PMID: 33385773 DOI: 10.1016/j.jcrc.2020.12.009] [Reference Citation Analysis]
24 Ferraris VA, Boral LI, Cohen AJ, Smyth SS, White GC. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev. 2015;23:53-68. [PMID: 25436468 DOI: 10.1097/crd.0000000000000045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 4.1] [Reference Citation Analysis]
25 Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2007;CD005011. [PMID: 17443565 DOI: 10.1002/14651858.cd005011.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 23] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ferraris VA, Ferraris SP, Saha SP. The Relationship Between Mortality and Preexisting Cardiac Disease in 5,971 Trauma Patients. Journal of Trauma: Injury, Infection & Critical Care 2010;69:645-52. [DOI: 10.1097/ta.0b013e3181d8941d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
27 Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011;154:516-22. [PMID: 21502649 DOI: 10.7326/0003-4819-154-8-201104190-00002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 73] [Article Influence: 8.5] [Reference Citation Analysis]